Detalhe da pesquisa
1.
YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells.
Nat Immunol
; 24(2): 255-266, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36658237
2.
MEETING HIGHLIGHTS: THE THIRD MARIE SKLODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2023.
Wiad Lek
; 76(12): 2543-2555, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38290016
3.
Myeloid cell-targeted miR-146a mimic inhibits NF-κB-driven inflammation and leukemia progression in vivo.
Blood
; 135(3): 167-180, 2020 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-31805184
4.
Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.
Mol Ther
; 29(3): 1214-1225, 2021 03 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33248246
5.
Large, Anionic Liposomes Enable Targeted Intraperitoneal Delivery of a TLR 7/8 Agonist To Repolarize Ovarian Tumors' Microenvironment.
Bioconjug Chem
; 32(8): 1581-1592, 2021 08 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289694
6.
B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Mol Ther
; 26(3): 695-707, 2018 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29433938
7.
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
Int J Mol Sci
; 20(8)2019 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31013891
8.
Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Cancer
; 124(6): 1216-1224, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29266182
9.
Revisiting TLR9 as a target for CLL therapy.
Blood
; 137(22): 3006-3008, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34081121
10.
Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Blood
; 127(13): 1687-700, 2016 Mar 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26796361
11.
Call for papers: Exploiting extracellular vesicles as therapeutic agents.
Mol Ther
; 30(3): 979, 2022 03 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35182469
12.
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.
Nat Rev Immunol
; 7(1): 41-51, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17186030
13.
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity.
Int J Mol Sci
; 19(6)2018 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29921770
14.
The revival of CpG oligonucleotide-based cancer immunotherapies.
Contemp Oncol (Pozn)
; 22(1A): 56-60, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29628795
15.
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Cancer Immunol Immunother
; 66(8): 979-988, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28214929
16.
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Blood
; 123(1): 15-25, 2014 Jan 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-24169824
17.
Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
J Urol
; 193(4): 1114-21, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25286010
18.
TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
Blood
; 121(8): 1304-15, 2013 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-23287859
19.
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
Mol Ther Nucleic Acids
; 35(1): 102137, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38384444
20.
Lipid Nanoparticle-Mediated Delivery of miRNA Mimics to Myeloid Cells.
Methods Mol Biol
; 2691: 337-350, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355556